Annual Reports

  • 10-K (Feb 28, 2014)
  • 10-K (Feb 28, 2013)
  • 10-K (Feb 28, 2011)
  • 10-K (Feb 26, 2010)
  • 10-K (Mar 2, 2009)
  • 10-K (Feb 29, 2008)

 
Quarterly Reports

 
8-K

 
Other

Edwards Lifesciences 8-K 2012

Documents found in this filing:

  1. 8-K
  2. 8-K

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported):  May 10, 2012

 

EDWARDS LIFESCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

 

1-15525

 

36-4316614

(State or other jurisdiction
of incorporation)

 

(Commission
file number)

 

(IRS Employer
Identification No.)

 

One Edwards Way, Irvine, California

 

92614

(Address of principal executive offices)

 

(Zip Code)

 

(949) 250-2500

Registrant’s telephone number, including area code

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.02.                                        Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

At the 2012 Annual Meeting of Stockholders of the Company (the “Annual Meeting”), stockholders of the Company approved the amendment and restatement of the Company’s Long-Term Stock Incentive Compensation Program (the “Long-Term Stock Program”) by the affirmative vote of a majority of the shares of common stock represented at the Annual Meeting, in person or by proxy, and entitled to vote.  Pursuant to the amended and restated Long-Term Stock Program, among other things, the total number of shares of common stock available for issuance under the Long-Term Stock Program was increased by 1,500,000 shares.  A more detailed description of the amended and restated Long-Term Stock Program is set forth in the Company’s Definitive Proxy Statement, filed March 30, 2012, under the Securities Exchange Act of 1934 (the “Proxy Statement”) in the sections entitled “The Long-Term Stock Incentive Compensation Program” and “Proposal 2—Amendment and Restatement of the Long-Term Stock Incentive Compensation Program” and is incorporated herein by reference.  Such description is qualified in its entirety by reference to the Long-Term Stock Program attached to the Proxy Statement as Appendix A and incorporated herein by reference as Exhibit 10.1.

 

Item 5.07.                                        Submission of Matters to a Vote of Security Holders

 

On May 10, 2012, the Company held its Annual Meeting of Stockholders.  The final results of voting for each matter submitted to a vote of stockholders at the meeting are as follows:

 

(i) Proposal 1 - All three nominees for director were elected to serve three-year terms ending in 2015, as follows:

 

 

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

Mike R. Bowlin

 

88,996,081

 

2,180,596

 

54,796

 

7,523,182

 

 

 

 

 

 

 

 

 

 

 

Barbara J. McNeil, M.D., Ph.D.

 

89,395,291

 

1,783,810

 

52,372

 

7,523,182

 

 

 

 

 

 

 

 

 

 

 

Michael A. Mussallem

 

87,180,007

 

3,983,536

 

67,930

 

7,523,182

 

 

(ii)  Proposal 2 — Approval of the Amended and Restated Long-Term Stock Program

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

82,207,609

 

8,896,842

 

126,814

 

7,523,390

 

 

(iii) Proposal 3 — Approval of the compensation of the Company’s named executive officers in a non-binding advisory vote

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

87,851,830

 

3,225,219

 

154,216

 

7,523,390

 

 

(iv) Proposal 4 — Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditors for the fiscal year ending December 31, 2012

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

96,692,565

 

1,972,101

 

89,989

 

0

 

 

(v) Proposal 5 — Approval of the stockholder proposal to declassify the Board of Directors in a non-binding advisory vote

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

87,900,166

 

1,036,893

 

1,137,548

 

8,680,048

 

 

(vi) Proposal 6 — Approval of the stockholder proposal to eliminate supermajority votes in a non-binding advisory vote

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

75,138,754

 

15,899,447

 

193,272

 

7,523,182

 

 

2



 

Item 9.01.                                        Financial Statements and Exhibits.

 

(d) Exhibits

 

10.1            Amended and Restated Long-Term Stock Incentive Compensation Program (incorporated by reference to Appendix A to the Company’s Definitive Proxy Statement, filed March 30, 2012, under the Securities Exchange Act of 1934.)

 

3



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: May 10, 2012

 

 

 

 

 

 

 

 

 

EDWARDS LIFESCIENCES CORPORATION

 

 

 

 

 

 

 

By:

/s/ Denise E. Botticelli

 

 

Denise E. Botticelli

 

 

Vice President, Associate General Counsel and Secretary

 

4


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki